MIAMI, FL — August 29, 2025 — Leads & Copy — Pasithea Therapeutics Corp. (NASDAQ: KTTA) has announced a change in the date and time of its management’s live presentation at the H.C. Wainwright 27th Annual Global Investment Conference in New York City. The presentation will now take place on Monday, September 8, at 5:00 PM Eastern Time.
Pasithea CEO, Dr. Tiago Reis Marques, will present and management will be available for one-on-one meetings during the conference, scheduled for September 8-10, 2025, at the Lotte New York Palace Hotel.
Pasithea is a clinical-stage biotechnology company focused on PAS-004, a next-generation macrocyclic MEK inhibitor for treating RASopathies, MAPK pathway-driven tumors, and other diseases. The company is testing PAS-004 in Phase 1 clinical trials for advanced cancer patients (NCT06299839) and adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NCT06961565).
Patrick Gaynes, Corporate Communications, pgaynes@pasithea.com
Source: Pasithea Therapeutics Corp.
